22-hydroxycholesterol has been researched along with Gall Bladder Diseases in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ji, ZL; Tan, YY; Wang, D; Wang, JM; Zhao, G | 1 |
1 other study(ies) available for 22-hydroxycholesterol and Gall Bladder Diseases
Article | Year |
---|---|
22(R)-hydroxycholesterol and pioglitazone synergistically decrease cholesterol ester via the PPARγ-LXRα-ABCA1 pathway in cholesterosis of the gallbladder.
Topics: ATP Binding Cassette Transporter 1; Cells, Cultured; Cholesterol Esters; Drug Synergism; Epithelial Cells; Gallbladder; Gallbladder Diseases; Humans; Hydroxycholesterols; Hypercholesterolemia; Liver X Receptors; Orphan Nuclear Receptors; Pioglitazone; PPAR gamma; Thiazolidinediones | 2014 |